SKIP Antibody

Introduction to SKIP Antibody

The SKIP antibody targets the protein encoded by the INPP5K gene, formally named skeletal muscle and kidney enriched inositol phosphatase. This enzyme regulates phosphoinositide signaling by hydrolyzing phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P3] and phosphatidylinositol (4,5)-bisphosphate [PI(4,5)P2], critical for cellular processes like cytoskeletal organization and membrane trafficking . SKIP is highly expressed in skeletal muscle and kidney tissues, with implications in congenital muscular disorders and metabolic regulation .

Gene and Protein Structure

• Gene: INPP5K (Chromosome 17p13.3) encodes a 42 kDa protein with a catalytic 5-phosphatase domain and a C-terminal SKICH domain for subcellular localization .

• Isoforms: Alternative splicing generates two isoforms (isoform 1: 416 amino acids; isoform 2: 401 amino acids) .

Functional Roles

• Actin Cytoskeleton Regulation: SKIP negatively regulates stress fiber formation by modulating PI(4,5)P2 levels, influencing cell motility and membrane dynamics .

• Disease Links: Mutations in INPP5K are associated with congenital muscular dystrophy with cataracts and intellectual disability (MDCCAID) and insulin signaling defects .

Research Applications of SKIP Antibodies

SKIP antibodies are critical tools for studying phosphoinositide metabolism and disease mechanisms. Key applications include:

Disease Associations

• Muscular Dystrophy: Biallelic INPP5K mutations disrupt ER homeostasis, leading to muscle atrophy and cataracts .

• Diabetes: SKIP modulates insulin-mediated PI3K/AKT signaling, with knockout models showing glucose intolerance .

Therapeutic Development

• Antibody Validation: Projects like YCharOS use knockout cell lines to confirm SKIP antibody specificity, a practice adopted by commercial vendors .

• Targeted Therapies: Recombinant SKIP antibodies show promise for restoring phosphoinositide balance in genetic disorders .

Challenges in SKIP Antibody Research

1. Specificity Issues: Only ~50% of commercial SKIP antibodies recognize their target in knockout-validated assays .

2. Epitope Mapping: Functional mapping of conformational epitopes remains technically demanding .

3. Standardization: Lack of universal protocols for cross-application validation (e.g., immunofluorescence vs. Western blot) .

Future Directions

• High-Throughput Screening: Platforms like PolyMap could profile SKIP antibody-antigen interactions across mutations .

• Multispecific Antibodies: Engineering bispecific antibodies to target SKIP and related phosphatases (e.g., SHIP1/2) may enhance therapeutic efficacy .